MYX 0.47% $4.26 mayne pharma group limited

Sell MYX and regret., page-5

  1. 6,917 Posts.
    lightbulb Created with Sketch. 431
    FROM WALL STREET JOURNAL
    2017 5-year trend
    1 Net Income Growth +137.10%
    Column 1
    0  
               
    Sales or Revenue| 572.60 M|
    Column 1 Column 2 Column 3 Column 4 Column 5
    0          
    Sales or Revenue Growth| +114.23%|
    Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 Column 7
    0              
    EBITDA| +195.93 M[/table]

    FY 2018 Estimate Trends
    1 Current: $0.04
    2 1 month ago: $0.04
    3 3 months ago: $0.04
    FY 2019 Estimate Trends
    1 Current: $0.05
    2 1 month ago: $0.05
    3 3 months ago: $0.05
    2017 5-year trend
    1 Cash & Short-Term Investment 71.02 M
    Column 1
    0  
           
    Total Debt| 340.25 M|
    Column 1 Column 2 Column 3 Column 4 Column 5
    0          
    Total Liabilities| 621.97 M|
    Column 1 Column 2 Column 3 Column 4 Column 5
    0          
    Total Shareholder's Equity| 1.30 B|
    Column 1 Column 2 Column 3 Column 4 Column 5
    0          
    Book Value Per Share| 0.86[/table]

    WOW
    LOOK at the capital expenditure 2017

    2017 5-year trend
    1 Capital Expenditures -1.08 B
    Column 1
    0  
                   
    Free Cash Flow| -119.65 M|
    Column 1 Column 2 Column 3 Column 4 Column 5 Column 6 Column 7 Column 8 Column 9
    0                  
    Cash Flow Per Share| -0.01| -
    Free Cash Flow Per Share| -0.08[/table]

    normalised free cash flow for July to Dec 2017 was 50 million plus and gross margins normalised 50%.
    How good is that. BV 86.
    Normally U get a stock like this for 5-7 times BV.
    And U think such huge CAPEX is going waste.
    No way.
    pRrofits will be pouring in from that capital expenditure.


    SUMMARY view is that MYX is way way undervalued considering its huge huge potential.
 
watchlist Created with Sketch. Add MYX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.